Romidepsin
Thymic Carcinoma
Roswell Park Cancer InstituteSmall moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 81/ 100
Competitive context
13 Active assets in the Thymic Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Beijing Biotech | Phase 2 | B |
Fludarabine Beijing Biotech | Phase 2 | B |
Evomela Roswell Park Cancer Institute | Phase 2 | B |
CYCLOSPORIN A Roswell Park Cancer Institute | Phase 2 | B |
Regorafenib Istituto Clinico Humanitas | Phase 2 | B |
View all 24 →
Same molecule, other indications
Romidepsin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →